Brief: Vincerx Pharma Presents Preclinical And Clinical Data On Ptefb/Cdk9 Inhibitor Vip152 In Lymphoma
10/06/2022 13:10
June 10 (Reuters) - Vincerx Pharma Inc VINC.O :
* VINCERX PHARMA PRESENTS PRECLINICAL AND CLINICAL DATA ON
PTEFB/CDK9 INHIBITOR VIP152 IN LYMPHOMA AT THE EUROPEAN
HEMATOLOGY ASSOCIATION 2022 CONGRESS
* VINCERX - DATA SHOW IMPROVED SELECTIVITY, TARGET
MODULATION,
EARLY SIGNS OF CLINICAL EFFICACY, CARDIAC SAFETY IN LYMPHOMA
PATIENTS TREATED WITH VIP152
Source text for Eikon: ID:nGNX5YQ12V
Further company coverage: VINC.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Vincerx Pharma
See all newsBrief: Vincerx Pharma Announces Intent To Delist From Nasdaq And Deregister With The SEC
Brief: Vincerx Pharma Announces Termination Of Letter Of Intent And Board Authorization To Pursue Wind-Down Activities
Vincerx Pharma Inc reports results for the quarter ended December 31 - Earnings Summary
Vincerx Pharma Inc expected to post a loss of $3.40 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Aditxt, Natgas companies, DocuSign